Bli medlem
Bli medlem

Du är här


Nordic Nanovector: Title: Nordic Nanovector announces successful closing of NOK 250 million pre-IPO private placement

Date: 18.06.2014        Press Release no: 16/2014

Nordic Nanovector is pleased to announce that it has closed its
pre-IPO private placement of 10,000,000 new shares at a price of NOK
25 per share for total gross proceeds of NOK 250 million. Completion
of the private placement is subject to resolution of an extraordinary
general meeting ("EGM"). The Company will hold an EGM by the end of
June 2014.

The private placement, which was directed towards existing
shareholders as well and new institutional and professional
investors, attracted strong investor interest and was increased from
NOK 150 million to NOK 250 million on the basis of strong demand from
solid institutional investors.

The private placement was managed by ABG Sundal Collier and DNB
Markets and was significantly oversubscribed. The Company's largest
shareholder, HealthCap VI L.P. participated in the placement and were
allocated 1,800,000 shares.

The Company intends to use the net proceeds of the Private Placement
to fund further clinical development of Betalutin™ for treatment of
non-Hodgkin Lymphoma.

The board of directors have decided to effect a subsequent repair
issue towards existing shareholders at the same subscription price as
in the offering. Further details will be announced in due course.

Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07

Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07

About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009.
The company is based in Norway and has offices and laboratories in
Oslo. The company is developing novel innovative anticancer
radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other
hematological malignancies.

About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a
radionuclide conjugated to a tumor seeking carrier/antibody, which
can be used for irradiation of malignant metastasized tumors with
minimal damage to nearby healthy normal tissue. This technology aims
to prolong and improve the quality of life of people who suffer from
non-Hodgkin Lymphoma (NHL).


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.